NextBio

Help
Description: A cycloheptathiophene blocker of histamine H1 receptors and release of inflammatory mediators. It has been proposed for the treatment of asthma, rhinitis, skin allergies, and anaphylaxis. [PubChem]
Drug Type: Small Molecule; Approved
Pharmacology: Ketotifen is a fast acting non-competitive histamine antagonist. It inhibits the release of mediators from mast cells. It is a non-bronchodilator antiasthmatic drug (when taken orally).
Mechanism of Action: Ketotifen is a relatively selective, non-competitive histamine antagonist (H1-receptor) and mast cell stabilizer. Ketotifen inhibits the release of mediators from mast cells involved in hypersensitivity reactions. Decreased chemotaxis and activation of eosinophils has also been demonstrated. Ketotifen also inhibits cAMP phosphodiesterase. Properties of ketotifen which may contribute to its antiallergic activity and its ability to affect the underlying pathology of asthma include inhibition of the development of airway hyper-reactivity associated with activation of platelets by PAF (Platelet Activating Factor), inhibition of PAF-induced accumulation of eosinophils and platelets in the airways, suppression of the priming of eosinophils by human recombinant cytokines and antagonism of bronchoconstriction due to leukotrienes. Ketotifen inhibits of the release of allergic mediators such as histamine, leukotrienes C4 and D4(SRS-A) and PAF.
Indication: Indicated as an add-on or prophylactic oral medication in the chronic treatment of mild atopic asthmatic children. Also for the temporary prevention of itching of the eye due to allergic conjunctivitis (ophthalmic).
Half Life: 21 hours (for elimination)
View Complete Description




Individual Studies
  • Drug target sets for approved compounds

    Homo sapiens Homo sapiens | Therapeutic   Therapeutic

    The DrugBank database is a unique bioinformatics and cheminformatics resource that combines detailed drug (i.e. chemical, pharmacological and pharmaceutical) data with comprehensive drug target (i.e. sequence, structure, and pathway) information.

    Authors: David S Wishart, Craig Knox, An Chi Guo et al.

    Organization: Department of Computing Science, Univers…

  • Broad Connectivity Map (CMAP 2.0) compound database

    Homo sapiens Homo sapiens | RNA Expression   RNA Expression

    A reference collection of genome-wide transcriptional expression data from cultured human cells treated with bioactive small molecules that enable the discovery of functional connections between drugs, genes and diseases through the transitory feature of common gene-expression changes.

    Authors: Lamb J

    Organization: Broad Institute Seven Cambridge Center C…

View All Individual Studies

Thought leaders and organizations working on research involving Ketotifen.

  • Takeo Tsujii
  • Takayuki Ohira
  • Shigeru Watanabe
  • Mark B Abelson
  • Eriko Yamamoto
  • Vistakon Pharmaceuticals
  • UCB
  • GlaxoSmithKline
  • Bausch & Lomb, Inc.
  • Campus Bio-Medico University
  • University of Alexandria
  • Keio University
  • Jordan University of Science and Technology
  • Kyushu Institute of Technology
  • Schepens Eye Research Institute

Community

Help for Community
  • No NextBio users were found for “Ketotifen”.
    Complete your user profile with your interests, if you want others to find you within the NextBio community.

  • No NextBio groups were found for “Ketotifen”.
    Be the first to start a group and share your interests with others within the NextBio community.